{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:25:24Z","timestamp":1789514724048,"version":"build-2803163510"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The article explores a case study of a patient diagnosed with relapsing-remitting multiple sclerosis (RRMS) who, while receiving treatment with the anti-CD20 monoclonal antibody ofatumumab, developed psoriatic skin lesions. Initially, sharply demarcated, scaly, erythematous lesions were observed only in the anogenital area. After several weeks, additional lesions appeared on the ear lobes, scalp, and lower legs following subsequent administrations of ofatumumab. A comprehensive differential diagnosis of the skin lesions was performed, which included consideration of autoimmune chronic diseases, infectious disease manifestations, and skin carcinomas. Biopsies of the lesions were obtained and underwent histopathological examination. Based on the clinical presentation and further investigations, it was concluded that the skin lesions were an atypical adverse reaction to ofatumumab, manifesting as psoriasis. In addition to presenting this case, we analyze the spectrum of common adverse reactions associated with ofatumumab, as well as the occurrence of psoriasis following other anti-CD20 therapies. To the best of our knowledge, this is a rare, documented instance of psoriasis occurring in a patient receiving ofatumumab for the treatment of multiple sclerosis.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1595947","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T05:30:44Z","timestamp":1754976644000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Severe psoriasis skin lesions following ofatumumab treatment for multiple sclerosis"],"prefix":"10.3389","volume":"16","author":[{"given":"Wioletta Katarzyna","family":"\u017bukowicz-Wyrwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Markiet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsiana","family":"Damps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Ciarka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Karaszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Nowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II","volume":"28","author":"G\u00e4rtner","year":"2022","journal-title":"Multiple Sclerosis J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005516","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study","volume":"90","author":"Bar-Or","year":"2018","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1177\/13524585221079731","article-title":"Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3","volume":"28","author":"Hauser","year":"2022","journal-title":"5\u2009years. Mult Scler"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy356","article-title":"Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis","volume":"6","author":"Ciardi","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10381","article-title":"Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review)","volume":"22","author":"Pintea","year":"2021","journal-title":"Exp Ther Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241232277","article-title":"Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review","volume":"30","author":"Emma","year":"2024","journal-title":"Multiple Sclerosis J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/srt.13662","article-title":"Induction of psoriatic scalp and nail lesions in a patient treated with Ofatumumab: A potential autoimmune dysregulation induced by anti-CD 20 therapy","volume":"30","author":"Herzum","year":"2024","journal-title":"Skin Res Technology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241260564","article-title":"Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis","volume":"30","author":"K\u00f6lsche","year":"2024","journal-title":"Mult Scler"},{"key":"B10","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1177\/13524585241232283","article-title":"Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmas","volume":"30","author":"Pfeuffer","year":"2024","journal-title":"Mult Scler"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.24018\/ejmed.2023.5.3.1697","article-title":"Ocrelizumab-induced psoriasis in A patient with relapsing-remitting multiple sclerosis","volume":"5","author":"Esmaeili","year":"2023","journal-title":"Eur J Med Health Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1595947\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T05:30:44Z","timestamp":1754976644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1595947\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":11,"alternative-id":["10.3389\/fimmu.2025.1595947"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1595947","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"article-number":"1595947"}}